Gene Therapy for Advanced Melanoma : Selective Targeting and Therapeutic Nucleic Acids

Abstract EN

Despite recent advances, the treatment of malignant melanoma still results in the relapse of the disease, and second line treatment mostly fails due to the occurrence of resistance.

A wide range of mutations are known to prevent effective treatment with chemotherapeutic drugs.

Hence, approaches with biopharmaceuticals including proteins, like antibodies or cytokines, are applied.

As an alternative, regimens with therapeutically active nucleic acids offer the possibility for highly selective cancer treatment whilst avoiding unwanted and toxic side effects.

This paper gives a brief introduction into the mechanism of this devastating disease, discusses the shortcoming of current therapy approaches, and pinpoints anchor points which could be harnessed for therapeutic intervention with nucleic acids.

We bring the delivery of nucleic acid nanopharmaceutics into perspective as a novel antimelanoma therapeutic approach and discuss the possibilities for melanoma specific targeting.

The latest reports on preclinical and already clinical application of nucleic acids in melanoma are discussed.